AACR Science Series at the FDA
The AACR Science Series at the FDA sessions began in July 2012. This series brings scientific leaders to the FDA campus to present cutting-edge advances in cancer biology to FDA scientific review staff and to foster the development of relationships between FDA reviewers and external scientific experts. Since January 2013, the AACR has been offering CME credits for these sessions.”
T Cells as the Future of Cancer Immunotherapy, January 22, 2021
Antoni Ribas, MD, PhD, Director, Tumor Immunology Program, University of California Los Angeles Jonsson Comprehensive Cancer Center; AACR President (2020-2021) CME Information
Highlights of the AACR Annual Meeting 2019, July 26, 2019
Elizabeth M. Jaffee, MD, Deputy Director, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center; Dana and Albert “Cubby” Broccoli Professor of Oncology; AACR President (2018-2019)
Epigenetics, Dec. 7, 2015
Stephen B. Baylin, MD, Professor of Oncology and Medicine, Sidney Kimmel Comprehensive Cancer Center
Charles W.M. Roberts, MD, PhD, Director and Executive Vice President, Comprehensive Cancer Center, St. Jude Children’s Research Hospital
Highlights of the AACR Annual Meeting 2015, July 27, 2015
Carlos L. Arteaga, MD, Associate Director for Clinical Research; Director, Breast Cancer Research Program; and Director, Center for Cancer Targeted Therapies at Vanderbilt-Ingram Cancer Center; AACR President (2014-2015)
Lewis C. Cantley, PhD, Sandra and Edward Meyer Cancer Center at Weill Cornell Medical College
Novel Approaches to Rational Drug Design, Dec. 12, 2014
Nathanael Gray, PhD, Professor of Biological Chemistry and Molecular Pharmacology at Harvard Medical School and Cancer Biology at Dana-Farber Cancer Institute
Lawrence Marnett, PhD, Director of the A.B. Hancock Jr. Memorial Laboratory for Cancer Research, Mary Geddes Stahlman Professor of Cancer Research, Vanderbilt University
Highlights of the AACR Annual Meeting 2014, July 21, 2014
Charles L. Sawyers, MD, Chairman, Human Oncology and Pathogenesis Program; Marie-Josee and Henry R. Kravis Chair at Memorial Sloan Kettering Cancer Center; AACR President (2013-2014)
Scott W. Lowe, PhD, Chair of the Cancer Biology and Genetics Program and the Geoffrey Beene Cancer Research Center; Howard Hughes Medical Institute Investigator at Memorial Sloan Kettering Cancer Center
Novel Non-Invasive Techniques to Detect and Monitor Tumors, March 10, 2014
Victor E. Velculescu, MD, PhD, Director of Cancer Genetics, Ludwig Center at Johns Hopkins and Co-director of Cancer Biology, Johns Hopkins Kimmel Cancer Center
Daniel A. Haber, MD, PhD, Director, Massachusetts General Hospital Cancer Center; Isselbacher/Schwartz Professor of Oncology at Harvard Medical School
Targeting Metabolic Pathways in Hematologic Malignancies and Solid Tumors, November 4, 2013
Kenneth C. Anderson, MD, PhD (hon), Kraft Family Professor of Medicine, Harvard Medical School; Medical Director, Kraft Family Blood Center, Dana-Farber Cancer Institute; and Director, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute
Lewis C. Cantley, PhD, Director, Cancer Center, Weill Cornell Medical College of Cornell University
Highlights of the AACR Annual Meeting 2013, July 29, 2013
Frank P. McCormick, PhD, FRS, Director, UCSF Helen Diller Family Comprehensive Cancer Center; Associate Dean, UCSF School of Medicine; David A. Wood distinguished professorship of tumor biology and cancer research; AACR President (2012-2013) and Chair of the AACR Regulatory Science and Policy Subcommittee
Jeffrey A. Engelman, MD, PhD, Director, Center for Thoracic Cancers at Massachusetts General Hospital Cancer Center and Associate Professor of Medicine at Harvard Medical School
Rational Strategies for Developing BRAF Inhibitors: Rational Combinations; Overcoming Resistance, Jan. 14, 2013
Frank P. McCormick, PhD, FRS, Director, UCSF Helen Diller Family Comprehensive Cancer Center; Associate Dean, UCSF School of Medicine; David A. Wood distinguished professorship of tumor biology and cancer research; AACR President (2012-2013) and Chair of the AACR Regulatory Science and Policy Subcommittee
Gideon E. Bollag, PhD, CEO, Research, Plexxikon Inc.
Immunotherapies, Oct. 1, 2012
James P. Allison, PhD, Professor and Chair, The University of Texas MD Anderson Cancer Center; Department of Immunology in the Division of Basic Science Research, Deputy Director, David H. Koch Center for Applied Research in Genitourinary Cancers, Department of Genitourinary Medical Oncology and Research; Investigator, Howard Hughes Medical Institute
David L. Porter, MD, Jodi Fisher Horowitz professor in leukemia care excellence; Director, Blood and Marrow Transplantation, Hospital of the University of Pennsylvania
Highlights of the AACR Annual Meeting 2012, July 23, 2012
Frank P. McCormick, PhD, FRS, Director, UCSF Helen Diller Family Comprehensive Cancer Center; Associate Dean, UCSF School of Medicine; David A. Wood distinguished professorship of tumor biology and cancer research; AACR President (2012-2013) and Chair of the AACR Regulatory Science and Policy Subcommittee
Benjamin G. Neel, PhD, MD, director of research of the Princess Margaret Cancer Centre, University Health Network